PML and acute promyelocytic leukemia: Taken together, the sensitivity of ccRCC cell lines to ATO was comparable to NB4 cells, which are representative of acute promyelocytic leukemia where ATO is part of standard-of-care therapy (Lo-Coco et al, 2016), and higher than TNBC MDA-MB-231 cells, where ATO reportedly inhibits PML oncogenic functions (Martín-Martín et al, 2016) (Fig. EV5B,C).